Etrasimod

In response to the clinical pain points of patients with inflammatory bowel diseases such as ulcerative colitis and Crohn's disease, including repeated mucosal damage and easy disease recurrence that they face for a long time, etrasimod, as a novel oral sphingosine-1-phosphate (S1P) receptor modulator, selectively binds to S1P1 and S1P5 receptors, blocks the egress of lymphocytes from lymph nodes, and reduces the infiltration of inflammatory cells in the intestinal mucosa. It has demonstrated significant advantages in the induction of remission and maintenance treatment of mild to moderate active ulcerative colitis. Clinical studies for some of its indications also cover immune-related diseases such as Crohn's disease and atopic dermatitis, providing patients with a treatment option that does not require injection and has higher compliance.

At present, the number of patients with inflammatory bowel disease worldwide has exceeded 12 million, and the prevalence rate is increasing year by year, driving the continuous expansion of the market size of S1P receptor modulators. Etrasimod is the world's first oral S1P modulator approved for ulcerative colitis, with global sales exceeding USD 580 million in 2023. The original research patent is still under the protection period at present, and more than 10 domestic pharmaceutical companies have initiated the R&D and declaration of generic drugs. With the expiration of the patent and the expansion of indications in the future, its market release space is expected to be further increased.

CATO can provide a full set of impurity reference standards for the R&D and production processes of etrasimod API. All products meet the compliance requirements of multiple regulatory systems such as the Chinese Pharmacopoeia and FDA. Core impurities are in sufficient stock, which can immediately respond to customers' needs for R&D, declaration and quality control, helping relevant enterprises shorten the project cycle.